Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ
107.75
+1.39(+1.31%)
  • Volume:
    33,686
  • Day's Range:
    105.28 - 109.00
  • 52 wk Range:
    72.57 - 169.98

LGND Overview

Prev. Close
106.36
Day's Range
105.28-109
Revenue
240.42M
Open
105.28
52 wk Range
72.57-169.98
EPS
-0.475
Volume
33,686
Market Cap
1.82B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
128,931
P/E Ratio
-
Beta
1.12
1-Year Change
-0.43%
Shares Outstanding
16,882,751
Next Earnings Date
Nov 10, 2022
What is your sentiment on Ligand?
or
Vote to see community's results!

Ligand Pharmaceuticals Incorporated News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Ligand Pharma Tops Q2 EPS by 60c
    • ByInvesting.com-

    Ligand Pharma (NASDAQ:LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus...

  • Ligand Pharma Tops Q1 EPS by 10c
    • ByInvesting.com-

    Ligand Pharma (NASDAQ:LGND) reported Q1 EPS of $0.76, $0.10 better than the analyst estimate of $0.66. Revenue for the quarter came in at $45.7 million versus the consensus...

  • Barclays Stick to Their Buy Rating for Ligand Pharma
    • ByInvesting.com-

    Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Ligand Pharma (NASDAQ:LGND) on Thursday, setting a price target of $185, which is approximately 22.74% above...

Ligand Pharmaceuticals Incorporated Analysis

Ligand Pharmaceuticals Incorporated Company Profile

Ligand Pharmaceuticals Incorporated Company Profile

Employees
154

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuySell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Sell
SummarySellStrong BuyStrong BuyStrong BuyStrong Sell
  • $300 next week
    0
    • Earnings today.
      0
      • this could be another short squeeze
        3
        • Just bought
          0
          • let wall street bets know about this
            3
            • easy 300, high growth profitable company with lots of shorties to squeeze
              0
              • short squeeze, after the good earning result?
                0
                • short squeeze?
                  0
                  • Buy now
                    0
                    • What in the world
                      0